Spike S1 (B.1.1.7, Alpha Variant), Avi-His-Tag (SARS-CoV-2)

• Background:

  The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) . As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Receptor Binding Domain (RBD) of Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. It has been widely suggested that active as well as passive immunizations targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 offer promising protection against viral infection. However recent reports showed that a mutant strain first identified in the UK (B.1.1.7) exhibits higher transmissibility and infectivity. Investigations on the effects of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19.

• Description:

  Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.1.7, also known as variant Alpha, originally identified in the United Kingdom. It contains mutations N501Y, A570D, D614G, P681H, and deletions 69-70HV and 144Y. The construct also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis) . The recombinant protein was affinity purified.

• Tag:

  C-terminal Avi-His-Tag

• Purity:

  ≥ 90%

• Format:

  Aqueous buffer solution.

• Shipping Conditions:

  -80°C

• Storage Conditions:

  At least 6 months at -80°C.

• Calculated Molecular Weight:

  78 kDa + glycans

• Formulation:

  8 mM phosphate pH 7.4,110 mM NaCl, 2.2 mM KCl, 20% glycerol

• Glycosylation:

  This protein runs at higher MW by SDS-PAGE due to glycosylation.